BioMedNewsBreaks

MondayNov 04, 2019 10:58 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Issues Lung Cancer Prevention Measures in Support of Lung Cancer Awareness Month

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) today announced that it is publishing lung cancer prevention measures in an effort to educate the public, prevent new cases and raise awareness in support of November’s Lung Cancer Awareness Month. According to the update, each case is unique, but several preventative actions may lower the risk of lung cancer, including avoiding or quitting smoking, reducing exposure to secondhand smoke and radon, and knowing one’s familial history with lung cancer. Genprex is developing potentially life-changing technologies for cancer patients, based upon a unique proprietary technology platform, including its initial product candidate, Oncoprex(TM) immunogene…

Continue Reading

WednesdayOct 09, 2019 9:44 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Announces Plans to Present at Inaugural MicroCap Rodeo Investor Conference

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) today announced its plans to present at the upcoming inaugural MicroCap Rodeo Investor Conference to be held at the Hilton Austin - Downtown in Austin, Texas. Genprex’s presentation is scheduled to take place on Tuesday, October 15 at 9:10 a.m. Central Time, led by its Chairman and CEO Rodney Varner, who will also be available for one-on-one meetings with investors. In addition, the presentation will be available via live webcast, with an archived recording to be provided for later viewing. To view the full press release, visit http://nnw.fm/sISn1 About Genprex, Inc. Genprex, Inc.…

Continue Reading

MondayOct 07, 2019 10:37 am

BioMedNewsBreaks – Genprex, Inc.’s (NASDAQ: GNPX) Pioneering Use of Non-Viral Vector Delivery for Gene Therapy Validated by Additional Industry Research

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) today announced additional research in the field validating non-viral vector delivery as the next evolution in gene therapy. Per the update, a recently published paper titled, “Encapsulation, Visualization and Expression of Genes with Biomimetically Mineralized Zeolitic Imidazolate Framework-8 (ZIF-8),” by researchers in Australia, Spain and Austria, supports the belief that non-viral delivery could be a safer alternative for patients than viral vectors, also potentially speeding production time while reducing costs. Genprex was not involved in the study that used a different nanotechnology. “One of the biggest differentiators between Genprex and other gene therapy…

Continue Reading

WednesdaySep 25, 2019 10:48 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Highlighted in Editorial on Potential Breast Cancer Treatments

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced its placement in an editorial published by BioMedWire ("BMW"), a multifaceted financial news and publishing company for private and public entities. The publication, titled “Gene Therapies with Potential to Conquer Tough-to-Tackle Breast Cancers,” may be accessed via the following link: http://nnw.fm/pNKm2. The editorial reads,“‘Disruptive’ isn’t a term that’s often applied to medicine, where the aim is to avoid disrupting the health of the human body. But technology such as Genprex Inc.’s (NASDAQ: GNPX) Oncoprex(TM) immunogene therapy is disruptive precisely because it could improve doctors’ ability to preserve health. It may…

Continue Reading

WednesdaySep 18, 2019 10:22 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) CEO to Present Via Webcast at September 19 Singular Research Midwestern Values Conference

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced that it will present, via webcast, at the Singular Research Midwestern Values Conference on September 19, 2019. Genprex Chairman and CEO Rodney Varner will lead the company's webcast presentation. The presentation is scheduled to begin at 4:00 PM Central Time, and interested parties may register for the webcast via the Singular Research website. To view the full press release, visit http://nnw.fm/IxlP7 About Genprex, Inc. Genprex, Inc. is a clinical stage gene therapy company developing potentially life-changing technologies for cancer patients, based upon a unique proprietary technology platform, including Genprex’s initial…

Continue Reading

WednesdaySep 11, 2019 10:17 am

BioMedNewsBreaks – Genprex, Inc.’s (NASDAQ: GNPX) TUSC2 Found to Prevent Tumor Growth in Triple-Negative Breast Cancer by Independent Researchers

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced that non-affiliated, independent researchers have reported in a recent study that TUSC2, a tumor suppressor gene and the active agent in Genprex’s Oncoprex(TM) immunogene therapy, prevented tumor growth in triple-negative breast cancer (“TNBC”). Currently considered an incurable cancer, there are limited therapeutic options available for TNBC. “The results of the study evaluating TUSC2 for the treatment of triple-negative breast cancer are encouraging,” Genprex Chairman and CEO Rodney Varner said in the news release. “We believe that the data reported in this Nature article by independent researchers supports our belief that…

Continue Reading

ThursdaySep 05, 2019 9:19 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Issues Corporate Update; Set to Present at H.C. Wainwright 21st Annual Global Investment Conference

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) on Tuesday issued an update regarding its clinical development programs, manufacturing and strategy for bringing its Oncoprex(TM) immunogene therapy to market. A corporate presentation is available on GNPX’s website which details anticipated milestones and future guidance for the company. “These milestones emphasize our commitment to developing potentially life-changing gene technologies for cancer patients who need them most,” Genprex chairman and chief executive officer Rodney Varner stated in the news release. “We continue to dedicate our efforts toward developing Oncoprex for non-small cell lung cancer (“NSCLC”) and we believe that achievement of these milestones…

Continue Reading

WednesdayAug 21, 2019 10:12 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Chairman and CEO to Present at the 4th Annual Disruptive Growth Conference

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced that its Chairman and Chief Executive Officer, Rodney Varner, is scheduled to present at the 4th Annual Disruptive Growth Conference. ReedSmith is hosting the event, which features growth companies with disruptive technologies and business models across a variety of sectors, at its offices at 599 Lexington Avenue in New York City on September 4, 2019. The Genprex presentation is slated for 5:00 p.m. to 5:15 p.m. Eastern Time in Presentation Room A/B. To view the full press release, visit http://nnw.fm/oGep8 About Genprex, Inc. Genprex, Inc. is a clinical stage gene…

Continue Reading

TuesdayAug 13, 2019 9:59 am

BioMedNewsBreaks – Genprex, Inc. (NASDAQ: GNPX) Announces Recent Achievements as Part of Overall Expansion Strategy

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced its recent achievements as part of the company’s overall strategy to expand its clinical development programs and bring its lead drug candidate, Oncoprex(TM) immunogene therapy, to commercialization. Per the update, Genprex has published recent as well as historical achievements to its newly launched, interactive corporate timeline, which can be found on the company’s website. “Since Genprex’s IPO last year, we have made significant progress in many areas of the company, including progress toward expansion of our clinical programs and sponsored research, our manufacturing process development and scalability, and the growth…

Continue Reading

TuesdayAug 06, 2019 11:02 am

BioMedNewsBreaks – Genprex, Inc.’s (NASDAQ: GNPX) Manufacturing Partner Aldevron Completes Significant Manufacturing Step for Initial Product Candidate, Oncoprex(TM)

Clinical-stage gene therapy company Genprex (NASDAQ: GNPX) this morning announced that its manufacturing partner, Aldevron, has successfully completed the manufacturing of the TUSC2 (Tumor Suppressor Candidate 2) plasmid DNA per the manufacturing agreement between the companies that was disclosed in September 2018. According to the update, Genprex’s Oncoprex(TM), the company’s initial product candidate, consists of a TUSC2 plasmid DNA manufactured by Aldevron encapsulated in a nanovesicle made from lipid molecules with a positive electrical charge. Historically, manufacturing steps have been done for Genprex at MD Anderson Cancer Center, but, since Genprex’s IPO, the company has been working to transfer and…

Continue Reading